Venrock Healthcare Capital Partners III, L.P.

Venrock Healthcare Capital Partners III, L.P., 10% owner at Lycia Therapeutics, Inc., has 6 open-market purchases worth $38,298,574 in company stock reported to the SEC in the last two years. The latest filing was reported on 2026-10-30.

In plain English

A 10%+ shareholder bought $236,653 of Lycia Therapeutics, Inc. stock with their own money. A decent-sized purchase. (2026-10-30)
A 10%+ shareholder bought $26,330 of Lycia Therapeutics, Inc. stock with their own money. A small purchase, so treat it as a mild signal. (2026-10-30)
A 10%+ shareholder bought $381,728 of Lycia Therapeutics, Inc. stock with their own money. That is a big personal bet. (2026-10-30)
A 10%+ shareholder bought $1,059,396 of Lycia Therapeutics, Inc. stock with their own money. That is a big personal bet. (2026-10-27)
A 10%+ shareholder bought $35,222,791 of Lycia Therapeutics, Inc. stock with their own money. That is a big personal bet. (2026-10-27)
A 10%+ shareholder bought $1,371,676 of Lycia Therapeutics, Inc. stock with their own money. That is a big personal bet. (2026-10-27)

Filings

Reported	Stock	What	Amount	Source
2026-10-30	LYCA Lycia Therapeutics, Inc.	Bought	$236,653	SEC filing
2026-10-30	LYCA Lycia Therapeutics, Inc.	Bought	$26,330	SEC filing
2026-10-30	LYCA Lycia Therapeutics, Inc.	Bought	$381,728	SEC filing
2026-10-27	LYCA Lycia Therapeutics, Inc.	Bought	$1,059,396	SEC filing
2026-10-27	LYCA Lycia Therapeutics, Inc.	Bought	$35,222,791	SEC filing
2026-10-27	LYCA Lycia Therapeutics, Inc.	Bought	$1,371,676	SEC filing

All insider buys · Legends · Executives

TradeTrack shows public SEC filings for general information. It is not investment advice, an offer or a recommendation. Insiders buy and sell for many reasons, past results do not predict future results, and you can lose money.